Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CANF | Can-Fite Biopharma Ltd ADR

Healthcare | Biotechnology | Israel | AMEX

Index	-	P/E	-	EPS (ttm)	-3.10	Insider Own	-	Shs Outstand	2.72M	Perf Week	-7.41%
Market Cap	10.20M	Forward P/E	-	EPS next Y	-2.58	Insider Trans	-	Shs Float	-	Perf Month	-9.42%
Income	-9.77M	PEG	-	EPS next Q	-0.61	Inst Own	1.34%	Short Float / Ratio	- / 1.43	Perf Quarter	-17.22%
Sales	0.79M	P/S	12.91	EPS this Y	7.26%	Inst Trans	-	Short Interest	0.02M	Perf Half Y	8.70%
Book/sh	1.68	P/B	1.48	EPS next Y	7.54%	ROA	-75.79%	Target Price	17.33	Perf Year	-66.80%
Cash/sh	2.36	P/C	1.06	EPS next 5Y	-	ROE	-116.52%	52W Range	1.52 - 9.00	Perf YTD	-59.22%
Dividend	-	P/FCF	-	EPS past 5Y	42.38%	ROI	-141.65%	52W High	-72.22%	Beta	1.31
Dividend %	-	Quick Ratio	4.89	Sales past 5Y	56.33%	Gross Margin	-	52W Low	64.47%	ATR	0.15
Employees	-	Current Ratio	4.89	Sales Q/Q	-3.92%	Oper. Margin	-1280.20%	RSI (14)	40.55	Volatility	5.44% 4.57%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	49.44%	Profit Margin	-1231.78%	Rel Volume	0.19	Prev Close	2.50
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 31 BMO	Payout	-	Avg Volume	10.67K	Price	2.50
Recom	1.00	SMA20	-8.63%	SMA50	-10.30%	SMA200	-22.37%	Volume	1,166	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-17	Initiated	Maxim Group	Buy	$7
Oct-19-16	Resumed	ROTH Capital	Buy
Aug-29-16	Resumed	Rodman & Renshaw	Buy	$6
Nov-30-15	Reiterated	H.C. Wainwright	Buy	$4 → $6
Mar-31-15	Reiterated	H.C. Wainwright	Buy	$7 → $3
Mar-30-15	Downgrade	ROTH Capital	Buy → Neutral	$20 → $2.40
Dec-29-14	Reiterated	ROTH Capital	Buy	$28 → $20
Nov-18-14	Initiated	H.C. Wainwright	Buy	$7

Sep-27-23 07:00AM	Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) (Business Wire)
Sep-07-23 07:00AM	Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference (Business Wire)
Aug-31-23 07:00AM	Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies (Business Wire)
Aug-24-23 07:10AM	Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome (Business Wire)
Aug-18-23 07:00AM	Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis (Business Wire)
07:00AM	Loading…
Aug-08-23 07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Jul-17-23 07:00AM	Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation (Business Wire)
Jul-11-23 07:00AM	Presenting on the Emerging Growth Conference on July 12 & 13 Register Now (GlobeNewswire)
Jul-07-23 07:00AM	Can-Fite to Present at the Emerging Growth Conference on July 13, 2023 (Business Wire)
Jun-29-23 07:00AM	Can-Fite Receives U.S. FDAs Go Ahead for Piclidenoson Psoriasis Registration Plan (Business Wire)
Jun-14-23 12:17PM	Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer (Zacks) +6.46%
Jun-13-23 07:00AM	Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson (Business Wire) +11.36%
Jun-02-23 07:00AM	Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston (Business Wire)
Jun-01-23 07:00AM	Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update (Business Wire)
May-30-23 07:00AM	Can-Fite: Namodenosons Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) (Business Wire) +10.04%
07:00AM	Loading…
May-15-23 07:00AM	Can-Fite: Presenting Namodenosons New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023 (Business Wire)
May-10-23 12:00PM	All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy (Zacks)
May-09-23 07:00AM	Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients (Business Wire)
May-02-23 07:00AM	Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists (Business Wire) +14.29%
Apr-24-23 07:00AM	Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization (Business Wire)
Apr-10-23 07:00AM	Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment (Business Wire)
Mar-30-23 07:15AM	Can-Fite Reports 2022 Financial Results & Provides Clinical Update (Business Wire) +5.65%
Mar-16-23 07:00AM	Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson (Business Wire)
Mar-13-23 07:00AM	Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting (Business Wire)
Feb-14-23 07:00AM	Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo (Business Wire) -6.36%
Jan-24-23 07:00AM	Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical StudiesA Patent Has Been Filed (Business Wire) -6.32%
Jan-11-23 09:04AM	Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement (Business Wire) -16.13%
Jan-10-23 07:00AM	Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow (Business Wire)
Dec-30-22 04:30PM	Can-Fite Announces ADS Ratio Change (Business Wire) -5.69%
Dec-29-22 10:18AM	Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA (Zacks)
10:21AM	Loading…
Dec-28-22 10:21AM	Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer (Benzinga) +8.17%
07:00AM	Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer (Business Wire)
Dec-27-22 08:00AM	Multiple Shots On Goal: Can-Fites Late-Stage Clinical Pipeline Hits Positive Results (News Direct) -6.26%
Dec-08-22 07:00AM	Can-Fites Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets Osteoarthritis (Business Wire)
Nov-25-22 07:00AM	Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update (Business Wire)
Nov-10-22 02:13PM	Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates (Zacks)
Nov-04-22 10:54AM	Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat (Zacks)
10:40AM	Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss (Zacks)
Nov-02-22 07:15AM	Can-Fite: Positive New Data from its Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston (Business Wire)
Oct-31-22 09:15AM	This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers (News Direct)
Oct-25-22 07:00AM	Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting® (Business Wire) +10.02%
Oct-13-22 07:00AM	Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference (Business Wire)
Sep-23-22 08:00AM	Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) -7.79%
Sep-12-22 07:00AM	Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology (Business Wire)
Aug-25-22 07:00AM	Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update (Business Wire) +9.70%
Aug-23-22 07:00AM	Can-Fites Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania (Business Wire) +7.15%
Aug-22-22 07:00AM	Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress (Business Wire)
Aug-17-22 07:25AM	Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix (Business Wire)
Jul-11-22 07:00AM	Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis (Business Wire) +12.22%
Jun-29-22 07:46AM	Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial (Benzinga) +15.62%
07:00AM	Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis (Business Wire)
Jun-24-22 07:00AM	Can-Fites CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia (Business Wire)
Jun-09-22 07:00AM	Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal (Business Wire)
May-26-22 07:00AM	Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update (Business Wire)
May-16-22 07:00AM	Can-Fite Granted Key NASH Patent in Israel (Business Wire)
May-02-22 07:00AM	Can-Fites CEO to Present Namodenosons Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit (Business Wire)
Apr-05-22 07:00AM	Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug (Business Wire)
Mar-28-22 07:00AM	Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022 (Business Wire)
Mar-24-22 08:30AM	Can-Fite Reports 2021 Financial Results & Provides Clinical Update (Business Wire) +12.75%
Mar-14-22 07:00AM	Can-Fite: Namodenosons Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office (Business Wire)
Mar-11-22 07:00AM	Can-Fites Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv (Business Wire)
Mar-08-22 08:35AM	Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study (Benzinga) -8.11%
07:00AM	Can-Fites Phase III Psoriasis Study Data Expected Q2 2022 (Business Wire)
Jan-31-22 07:00AM	Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson (Business Wire)
Jan-13-22 08:44AM	Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows (Benzinga)
07:00AM	Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro (Business Wire)
Jan-10-22 07:26AM	Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference (Business Wire) +7.03%
Jan-05-22 07:00AM	Can-Fite Issues Letter to Shareholders (Business Wire)
Dec-30-21 10:58AM	Can-Fite (CANF) Files Patent Applications for Namodenoson (Zacks) -8.28%
Dec-29-21 10:49AM	CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today (InvestorPlace) +15.08%
07:00AM	Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors (Business Wire)
Dec-21-21 09:18AM	Company News for Dec 21, 2021 (Zacks) -32.09%
Dec-20-21 04:05PM	Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million (GlobeNewswire) +69.29%
02:01PM	Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient (Benzinga)
12:08PM	CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today (InvestorPlace)
07:00AM	Liver Cancer Patient Treated with Can-Fites Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study (Business Wire)
Dec-07-21 07:00AM	Can-Fites Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022 (Business Wire)
Nov-26-21 07:00AM	Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update (Business Wire)
Nov-24-21 07:00AM	Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021 (Business Wire)
Nov-23-21 07:00AM	Can-Fites Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis (Business Wire)
Nov-12-21 07:00AM	Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference (Business Wire)
Nov-01-21 07:00AM	Can-Fites Findings on Cannabis Compounds Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLDs The Liver Meeting® 2021 Conference (Business Wire)
Oct-28-21 07:00AM	Can-Fites NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico (Business Wire)
Oct-26-21 07:00AM	Can-Fite CEO to Present Namodenosons Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit (Business Wire)
Oct-21-21 09:25AM	Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal (Benzinga)
07:00AM	Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal (Business Wire)
Oct-20-21 10:32AM	Race to Effective Psoriasis Treatment: Can-Fite's Piclidenoson May Edge Over High-Flying Amgen's Otezla. Here's Why (Benzinga)
Oct-08-21 08:48AM	Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial (Benzinga)
Oct-05-21 07:00AM	Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 (Business Wire)
Sep-22-21 07:00AM	Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021 (Business Wire)
Sep-17-21 07:00AM	Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences (Business Wire)
Sep-09-21 07:00AM	Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Sep-02-21 07:00AM	Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study (Business Wire)
Aug-26-21 07:00AM	Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update (Business Wire)
Aug-12-21 08:00AM	Can-Fite Announces $10.0 Million Registered Direct Offering (Business Wire) -5.29%
Aug-05-21 09:18AM	Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board (Business Wire)
Jul-08-21 07:00AM	Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study (Business Wire)
Jun-28-21 09:11AM	Can-Fite Stock Gains On Piclidenoson Development Pact For Pets (Benzinga)
07:00AM	Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets (Business Wire)
Jun-16-21 07:45AM	Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment (Business Wire)

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CANF | Can-Fite Biopharma Ltd ADR

Upgrade your FINVIZ experience